Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives

doi:10.4251/wjgo.v17.i4.101528

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (66)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=63

Apr 15, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 101528
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.101528

Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives

Yu-Run Miao, Xiao-Jun Yang

Yu-Run Miao, The First Clinical Medical School, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China

Yu-Run Miao, Xiao-Jun Yang, Second Ward of General Surgery, Gansu Province People Hospital, Lanzhou 730000, Gansu Province, China

Author contributions: Miao YR designed the overall concept and outline of the manuscript; Yang XJ contributed to the discussion and design of the manuscript; Miao YR and Yang XJ contributed to this paper, the writing, and editing the manuscript, and review of literature; all of the authors read and approved the final version of the manuscript to be published.

Supported by The National Health Commission's Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment for the Year 2022, National Health Commission's Master's and Doctoral/Postdoctoral Fund Project, No. NHCDP2022001; and Gansu Provincial People's Hospital Doctoral Supervisor Training Project, No. 22GSSYA-3.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Jun Yang, MD, Associate Professor, Chief Physician, Second Ward of General Surgery, Gansu Province People Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. yangxjmd@aliyun.com

Received: September 18, 2024
Revised: December 31, 2024
Accepted: January 8, 2025
Published online: April 15, 2025
Processing time: 188 Days and 11.8 Hours

Core Tip

Core Tip: This study reveals the potential clinical value of Rho GTPase activating protein 12 (ARHGAP12) and provided the target direction for clinical tyrosine kinase inhibitor resistance and highlights the potential role of ARHGAP12 in drug resistance by revealing its involvement in the focal adhesion pathway. Through gene enrichment and protein-protein interaction network analyses, it was found that ARHGAP12 might regulate integrin beta 1, impacting cell attachment, migration, and cytoskeleton interactions.